WGS — GeneDx Holdings Corp.

Summary of GeneDx Holdings Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $102.3 million, including $90.6 million from exome and genome testing, representing a 27% increase year-over-year.
• Test Volume: 27,488 tests conducted, up 34% year-over-year.
• Blended Average Reimbursement Rate (ARR): Approximately $3,300, which was lower than expected due to product mix shifts.
• Adjusted Gross Margin: 69%.
• Adjusted Net Loss: $8.2 million.
• Revenue Guidance for 2026: Revised to $475 million to $490 million, reflecting a 12% reduction from previous expectations.

2. Strategic Updates and Business Highlights

• GeneDx is transitioning from multi-gene panels to comprehensive exome and genome testing, with a focus on leveraging their large dataset, GeneDx Infinity.
• The company is integrating the Fabric Genomics acquisition into its brand to enhance international growth and streamline operations.
• A new Reflex offering was launched to balance clinical demand with higher gross margins.
• The sales force has been expanded to improve market penetration across various segments, including NICU and general pediatrics.

3. Forward Guidance and Outlook

• Q2 2026 Expectations: Total revenues projected between $110 million to $112 million, with exome and genome volume around 30,000 tests and adjusted net loss of approximately $5 million.
• Long-term Growth: Anticipated volume growth of at least 30% for exome and genome testing, with a commitment to achieving adjusted profitability by the end of 2026.
• Focus Areas: Improving reimbursement rates, optimizing unit economics, and enhancing product offerings.

4. Bad News, Challenges, or Points of Concern

• Revenue Shortfall: Total revenue was $12 million lower than expected due to a lower blended average reimbursement rate and underperformance in non-core business lines.
• Non-Core Business Performance: Revenue from Fabric and biopharma fell short by $6.5 million, leading to a non-cash impairment charge of approximately $31.3 million.
• Market Dynamics: The transition to genome testing has been slower than anticipated, with reimbursement rates for genome tests currently lower than those for exome tests.
• Sales Cycle Delays: Longer sales cycles in the biopharma segment are impacting revenue realization.

5. Notable Q&A Insights

• Management acknowledged the need for improved forecasting and tighter channel management to address the lower-than-expected ARR.
• The company is confident in the momentum within the NICU segment and believes that adjustments to sales strategies will yield results.
• There is optimism regarding the potential for genome reimbursement rates to improve over time as clinical evidence accumulates and payer policies evolve.
• The sales force expansion is still in early stages, with productivity expected to increase as new reps gain experience.
• Management emphasized a disciplined approach to guidance, focusing on established markets while treating new markets as upside opportunities.

Overall, while GeneDx Holdings Corp. demonstrated strong volume growth and strategic initiatives aimed at enhancing their market position, challenges related to reimbursement rates and non-core business performance have necessitated a cautious outlook for the remainder of 2026.